Skip to content
Bored Studies
RecruitingPhase 2

Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)

Evon Medics LLC · with National Institute of Neurological Disorders and Stroke (NINDS), Howard University · NCT06671132

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–85 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
220
US sites recruiting
2
Study start
October 23, 2024
Record last updated
November 4, 2024

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The overarching goal of this study phase, Phase II component is to perform a randomized clinical trial of the refined Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain [CBOT-Pain (or CBOT-P)] from Phase I, compared to sham Computerized Chemosensory-Based Orbitofrontal Networks Training (CBOT) in Chronic Low Back Pain (CLBP) to determine its short- and long-term effectiveness on Pain, Negative Affect (NA), Cognition and Cortical Brain Structure (PACS), long-term safety, and indications.

The investigators will perform a randomized clinical trial of the refined CBOT-P from Phase I, compared to sham CBOT in CLBP.

Aim 2.1: To determine if CBOT-P significantly influences: (1) acute and long-term reduction of pain severity, and (2) acute and long-term reduction of negative affect. The hypothesis is that optimized CBOT will produce faster, stronger, and longer-lasting improvements in pain severity, NA severity, cognitive impairments, and sleep and functional outcomes.

Aim 2.2 To determine if CBOT-P significantly prevents or reduces progressive shrinkage in the orbitofrontal cortex (OFC), cingulate cortex, and hippocampus. MRI will be acquired at baseline and 6th month. An integrative analysis will be conducted to determine the link between changes in brain structure and cognitive trajectory. The hypothesis is that the CBOT optimized with BCP significantly attenuates shrinkage in OFC and other prefrontal cortex (PFC) regions, compared to the Sham intervention.

Being studied: Computerized Chemosensory-Based Orbitofrontal Cortex Training for Pain; Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)

Conditions: Chronic Pain; Low Back Pain

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Ages 18-85.
  • Pain duration > 6 months.
  • Must meet the minimum criteria for cognitive function using the PROMIS 4-item cognitive screener >3.
  • Average pain score of > 5/10, with low back pain being the primary pain site. (5) CLBP (chronic low back pain) meeting Quebec Task Force Classification System Categories I-III.

(6) Evidence of a prior lumbar spine X-ray to rule out red flags, such as infection, tumor, or fracture.

(7) For those taking opioids (the opioid subgroup), participants must be prescribed opioids currently for at least 3 consecutive months prior to enrollment. Such patients must be on opioids for a minimum of three months, taking them daily or intermittently during the week. (8) Subject must agree that opioids cannot be increased during the study. (9) No substance use disorder (SUD), except tobacco in the past year based on substance screening survey and frequent urine toxicology screens. (10) No acute suicidality, mania, or psychosis. This will be assessed at study entry, which will also include a review of history in the EHR, Diagnostic Interview for Genetic Studies (DIGS) and Columbia Suicide Severity Rating scale (C-SSRS) and (11) Finally, participants must sign IRB-approved consent.

Exclusion Criteria

  • Back surgery within the past six months.
  • Active worker's compensation or litigation claims.
  • New pain and/or psychiatric treatments within 2 weeks of enrollment.
  • Intent to add new or increase pain treatments during the study period, such as back surgery, nerve block procedures, or medications.
  • Intent to add new psychiatric treatments during the first 3 months of the study.
  • Any clinically unstable systemic illness that is judged to interfere with the trial.
  • History of cardiac, nervous system, or respiratory disease that, in the investigator's judgment, precludes participation in the study because of a heightened potential for respiratory depression.
  • Non-ambulatory status.
  • Pregnancy or the intent to become pregnant during the study. Women of childbearing age will have urine pregnancy testing at enrollment and monthly. (10) Anosmia or significant nasal disease

(11) Contraindications to MRI (12) Stroke or TBI (traumatic brain injury).

Recruiting US locations

  • Howard University

    Washington D.C., DC 20060

    Site contact: Maria Hipolito, MD · 202-865-1751 · mhipolito@howard.edu

  • Global Pain Management LLC

    Pasadena, MD 21112

    Site contact: Opeyemi Awofeso, MD · 410-891-4007 · oawofeso@evonmedics.org

Study contacts (from the official record)

  • Evaristus Nwulia, M.D., MHS · 410-227-2005 · enwulia@evonmedics.org
  • Maria Hipolito, MD · 571-241-2766 · mhipolito@howard.edu
All neurology studies in District of Columbia →
Development and Evaluation of Computerized Chemosensory-Based… (NCT06671132) | Bored Studies